TY - JOUR
T1 - The thyromimetic T-0681 protects from atherosclerosis
AU - Tancevski, Ivan
AU - Wehinger, Andreas
AU - Demetz, Egon
AU - Hoefer, Julia
AU - Eller, Philipp
AU - Huber, Eva
AU - Stanzl, Ursula
AU - Duwensee, Kristina
AU - Auer, Kristina
AU - Schgoer, Wilfried
AU - Kuhn, Volker
AU - Fievet, Catherine
AU - Stellaard, Frans
AU - Rudling, Mats
AU - Foeger, Bernhard
AU - Patsch, Josef R.
AU - Ritsch, Andreas
PY - 2009/5
Y1 - 2009/5
N2 - This report describes studies in hyperlipidemic New Zealand White (NZW) rabbits investigating the impact of the liver-selective thyromimetic T-0681 on lipoprotein metabolism and the development of atherosclerosis. Prolonged treatment with T-0681 increased the hepatic expression of both LDL receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Upregulation of hepatic lipoprotein receptors was accompanied by a marked decrease of apolipoprotein B-containing lipoproteins, reflected by a 60% reduction of plasma cholesterol and a > 70% reduction of plasma triglyceride levels. Most importantly, T-0681 reduced the development of atherosclerosis by 80% in NZW rabbits on high-cholesterol chow. jlr Our data suggest that liver-selective thyromimetics, such as T-0681, may prove to be useful therapeutic agents against the development of atherosclerosis in humans.-Tancevski, I., A. Wehinger, E. Demetz, J. Hoefer, P. Eller, E. Huber, U. Stanzl, K. Duwensee, K. Auer, W. Schgoer, V. Kuhn, C. Fievet, F. Stellaard, M. Rudling, B. Foeger, J. R. Patsch, and A. Ritsch. The thyromimetic T-0681 protects from atherosclerosis. J. Lipid Res. 2009. 50: 938-944.
AB - This report describes studies in hyperlipidemic New Zealand White (NZW) rabbits investigating the impact of the liver-selective thyromimetic T-0681 on lipoprotein metabolism and the development of atherosclerosis. Prolonged treatment with T-0681 increased the hepatic expression of both LDL receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Upregulation of hepatic lipoprotein receptors was accompanied by a marked decrease of apolipoprotein B-containing lipoproteins, reflected by a 60% reduction of plasma cholesterol and a > 70% reduction of plasma triglyceride levels. Most importantly, T-0681 reduced the development of atherosclerosis by 80% in NZW rabbits on high-cholesterol chow. jlr Our data suggest that liver-selective thyromimetics, such as T-0681, may prove to be useful therapeutic agents against the development of atherosclerosis in humans.-Tancevski, I., A. Wehinger, E. Demetz, J. Hoefer, P. Eller, E. Huber, U. Stanzl, K. Duwensee, K. Auer, W. Schgoer, V. Kuhn, C. Fievet, F. Stellaard, M. Rudling, B. Foeger, J. R. Patsch, and A. Ritsch. The thyromimetic T-0681 protects from atherosclerosis. J. Lipid Res. 2009. 50: 938-944.
KW - liver-selective thyromimetic
KW - low density lipoprotein receptor
KW - scavenger receptor class B, type I
KW - potential side effects
KW - DENSITY-LIPOPROTEIN RECEPTOR
KW - REVERSE CHOLESTEROL TRANSPORT
KW - ESTER TRANSFER PROTEIN
KW - B TYPE-I
KW - LDL CHOLESTEROL
KW - MICE
KW - EXPRESSION
KW - APOLIPOPROTEIN
KW - LIVER
KW - HYPOTHYROIDISM
U2 - 10.1194/jlr.M800553-JLR200
DO - 10.1194/jlr.M800553-JLR200
M3 - Article
VL - 50
SP - 938
EP - 944
JO - Journal of Lipid Research
JF - Journal of Lipid Research
SN - 0022-2275
IS - 5
ER -